




Searching News Database: targeted therapy
HSMN NewsFeed - 9 Oct 2023
Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial
Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 29 Dec 2021
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
HSMN NewsFeed - 1 Apr 2019
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 26 Sep 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
HSMN NewsFeed - 2 Jun 2017
CardioNXT Raises $2.1M For Atrial Fibrillation Led By Industry Veterans Bullock and Hawkins
CardioNXT Raises $2.1M For Atrial Fibrillation Led By Industry Veterans Bullock and Hawkins
HSMN NewsFeed - 19 Oct 2016
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
HSMN NewsFeed - 4 Feb 2016
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 15 Oct 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
HSMN NewsFeed - 29 Jun 2015
Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals
Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals
HSMN NewsFeed - 1 Oct 2013
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
HSMN NewsFeed - 1 Oct 2012
Roche Diagnostics ACCU-CHEK Combo Insulin Pump System Now Available in United States
Roche Diagnostics ACCU-CHEK Combo Insulin Pump System Now Available in United States
HSMN NewsFeed - 2 Apr 2012
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
HSMN NewsFeed - 18 May 2011
Molecular Response Appoints Kenna Anderes, PhD, as Senior Vice President of Translational Medicine
Molecular Response Appoints Kenna Anderes, PhD, as Senior Vice President of Translational Medicine
HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 2 Feb 2009
Molecular Insight Pharmaceuticals Announces Board and Senior Management Appointments
Molecular Insight Pharmaceuticals Announces Board and Senior Management Appointments
HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
HSMN NewsFeed - 11 Mar 2008
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
HSMN NewsFeed - 29 Oct 2007
Thallion Provides Update on Shigamabs(R) Clinical Development and U.S. Regulatory Plan
Thallion Provides Update on Shigamabs(R) Clinical Development and U.S. Regulatory Plan
HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
HSMN NewsFeed - 25 Apr 2007
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
HSMN NewsFeed - 27 Feb 2007
Vaccinex Announces Antibody Development and Commercialization Alliance in Multiple Sclerosis and Oncology
Vaccinex Announces Antibody Development and Commercialization Alliance in Multiple Sclerosis and Oncology
HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
HSMN NewsFeed - 20 Feb 2007
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
HSMN NewsFeed - 25 Oct 2006
Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
HSMN NewsFeed - 15 Sep 2006
Schering AG and AstraZeneca Form Strategic Alliance to Develop Novel Anti-Cancer Drug
Schering AG and AstraZeneca Form Strategic Alliance to Develop Novel Anti-Cancer Drug
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Additional items found! 77

Members Archive contains
77 additional stories matching:
targeted therapy
(Password required)
targeted therapy
(Password required)